Lavaud et al. showed that showed that treatment of patients with severe occupational asthma due to low molecular weight agents, with the anti-IgE antibody omalizumab lowered the levels of total serum IgE and in most cases improved FEV1, but did not result in complete controlled asthma [9]. The gene discussed is IGHE; the disease is asthma.